Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free LSTA Stock Alerts

Lisata Therapeutics (LSTA) Competitors

Lisata Therapeutics logo
$1.26 -0.21 (-14.29%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$1.26 0.00 (0.00%)
As of 05:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LSTA vs. IMA, BKHA, TIL, ELTX, and HOWL

Should you buy Lisata Therapeutics stock or one of its competitors? Lisata Therapeutics's main competitors and comparable companies include ImageneBio (IMA), Black Hawk Acquisition (BKHA), Instil Bio (TIL), Elicio Therapeutics (ELTX), and Werewolf Therapeutics (HOWL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lisata Therapeutics compare to ImageneBio?

Lisata Therapeutics (NASDAQ:LSTA) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

ImageneBio has a consensus price target of $29.00, indicating a potential upside of 517.02%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts clearly believe ImageneBio is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
ImageneBio
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lisata Therapeutics had 2 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for ImageneBio. Lisata Therapeutics' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lisata Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ImageneBio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ImageneBio's return on equity of -38.99% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -116.08% -90.55%
ImageneBio N/A -38.99%-34.84%

Lisata Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Lisata Therapeutics has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K66.78-$16.59M-$1.64N/A
ImageneBio$800K66.68-$45.35M-$4.58N/A

Summary

ImageneBio beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Black Hawk Acquisition?

Lisata Therapeutics (NASDAQ:LSTA) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

8.9% of Lisata Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Black Hawk Acquisition's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -116.08% -90.55%
Black Hawk Acquisition N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Black Hawk Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Black Hawk Acquisition has lower revenue, but higher earnings than Lisata Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K66.78-$16.59M-$1.64N/A
Black Hawk AcquisitionN/AN/AN/AN/AN/A

Lisata Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

In the previous week, Lisata Therapeutics had 3 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 3 mentions for Lisata Therapeutics and 0 mentions for Black Hawk Acquisition. Lisata Therapeutics' average media sentiment score of 0.00 equaled Black Hawk Acquisition'saverage media sentiment score.

Company Overall Sentiment
Lisata Therapeutics Neutral
Black Hawk Acquisition Neutral

Summary

Lisata Therapeutics beats Black Hawk Acquisition on 6 of the 8 factors compared between the two stocks.

How does Lisata Therapeutics compare to Instil Bio?

Lisata Therapeutics (NASDAQ:LSTA) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Lisata Therapeutics had 3 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Lisata Therapeutics and 0 mentions for Instil Bio. Lisata Therapeutics' average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company Overall Sentiment
Lisata Therapeutics Neutral
Instil Bio Neutral

Instil Bio has a consensus price target of $7.00, indicating a potential upside of 0.72%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Lisata Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Instil Bio's return on equity of -26.78% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -116.08% -90.55%
Instil Bio N/A -26.78%-14.89%

Lisata Therapeutics has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K66.78-$16.59M-$1.64N/A
Instil BioN/AN/A-$71.37M-$4.47N/A

Summary

Instil Bio beats Lisata Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Lisata Therapeutics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Lisata Therapeutics had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Elicio Therapeutics. Lisata Therapeutics' average media sentiment score of 0.00 beat Elicio Therapeutics' score of -0.26 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elicio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lisata Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lisata Therapeutics' return on equity of -116.08% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Elicio TherapeuticsN/A -1,266.43% -139.94%
Lisata Therapeutics N/A -116.08%-90.55%

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lisata Therapeutics has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elicio TherapeuticsN/AN/A-$39.57M-$2.17N/A
Lisata Therapeutics$170K66.78-$16.59M-$1.64N/A

Elicio Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Elicio Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 681.25%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Elicio Therapeutics is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Lisata Therapeutics beats Elicio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, Lisata Therapeutics had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Werewolf Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lisata Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 330.11%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Lisata Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M24.04-$60.82M-$0.76N/A
Lisata Therapeutics$170K66.78-$16.59M-$1.64N/A

Lisata Therapeutics' return on equity of -116.08% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
Lisata Therapeutics N/A -116.08%-90.55%

Werewolf Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Werewolf Therapeutics beats Lisata Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LSTA vs. The Competition

Export
MetricLisata TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13.25M$3.85B$7.14B$13.26B
Dividend YieldN/A3.65%2.53%17.36%
P/E Ratio-0.7712.99274.3426.20
Price / Sales66.781,185.42577.5778.96
Price / CashN/A39.0427.2234.70
Price / Book0.7617.0511.236.40
Net Income-$16.59M-$23.20M$3.49B$381.07M
7 Day Performance-14.29%-2.16%-1.33%-0.30%
1 Month Performance-23.64%-10.24%-5.99%-4.53%
1 Year Performance-49.80%17.41%7.27%1.62%

Lisata Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LSTA
Lisata Therapeutics
0.4838 of 5 stars		$1.26
-14.3%		N/A-50.0%$13.25M$170KN/A21
IMA
ImageneBio
2.6595 of 5 stars		$4.58
flat		$29.00
+533.2%		-45.3%$51.99M$800KN/A18
BKHA
Black Hawk Acquisition
N/A$12.25
-0.9%		N/A+10.0%$51.34MN/AN/AN/A
TIL
Instil Bio
0.3587 of 5 stars		$7.24
+1.4%		$7.00
-3.3%		-61.6%$48.42MN/AN/A410
ELTX
Elicio Therapeutics
2.2037 of 5 stars		$1.82
-1.1%		$15.00
+724.2%		-82.6%$48.36MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
They're not telling you how bad this could get
Valuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...
Parkview Capital Group | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
This smart glasses tech is bringing the screen to your eyes
Global AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...
The Tomorrow Investor | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...
Paradigm Press | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
MAJOR BUY ALERT: Elon, Data Centers, Space
Stock picker Luke Lango recently toured Vegas and counted more than 60 new data centers under construction, ev...
InvestorPlace | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
This AI Stock Reminds One Analyst of Early Nvidia
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel